---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044224"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T03:07:07.308655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025

## Summary
- Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
- Vaccine safe and well tolerated; only notable side effect was injection-site irritation.
- Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).
- Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.
- Phase 2 neoadjuvant study with randomized control planned to commence in 2025.

## SEC filing metadata
- accession: 0001493152-24-044224
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/0001493152-24-044224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044224
- JSON: https://secwatch.observer/filing/0001493152-24-044224.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.